StephanieNovielloMD

Pediatrics • Bridgewater, NJ

Physician

Join to view full profile

Dr. Noviello is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Noviello's full profile

Already have an account?

Office
XX
Bridgewater, NJ 08807

Education & Training

Tulane University School of MedicineClass of 1997

Certifications & Licensure

NJ State Medical License 2000 - 2019
American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

5 citations
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Int...
David B. Huang, Stephanie Noviello, Barbara Balser, Amy Scaramucci, G. Ralph Corey
Clinical Therapeutics. 2019-06-01
8 citations
In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections
Stephanie Noviello, Sophie Magnet, Stephen Hawser, David B. Huang
Antimicrobial Agents and Chemotherapy. 2019-03-27
336 citations
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-contro...
Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander-Tetri, Rohit Loomba, Stephen A. Harrison
Lancet. 2018-12-22

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)
Mitchell L Shiffman, Stephanie Noviello, Gregory D Huhn, Antiviral Therapy

Press Mentions

Motif Bio Reports Fiscal Year 2018 ResultsApril 26th, 2019
Is Selling Motif Bio Plc (MTFB) Here a Winning Strategy?April 15th, 2019
Motif Bio Plc (MTFB) EPS Estimated at $-0.45; Silicom Ltd – Ordinary Shares (SILC) SI Decreased by 44.28%April 3rd, 2019
Join now to see all